A double-blind, placebo-controlled, dose-ranging study to investigate the safety and efficacy of CY 208-243 in patients with Parkinson's disease

We carried out a double-blind rising dose study of a D-1 dopamine agonist, CY 208-243, in 6 parkinsonian patients. Deficits monitored by Columbia scores were significantly improved at single doses ranging from 5 to 40 mg, though efficacy was low. Used alone, CY 208-243 was not a satisfactory therape...

Full description

Saved in:

Bibliographic Details
Published in:	Neurology Vol. 39; no. 6; pp. 856 - 858
Main Authors:	TSUI, J. K. C, WOLTERS, E. C, PEPPARD, R. F, CALNE, D. B
Format:	Journal Article
Language:	English
Published:	Hagerstown, MD Lippincott Williams & Wilkins 01-06-1989
Subjects:	Biological and medical sciences Catecholaminergic system Dose-Response Relationship, Drug Double-Blind Method Female Humans Indoles - adverse effects Indoles - therapeutic use Male Medical sciences Middle Aged Neuropharmacology Neurotransmitters. Neurotransmission. Receptors Parkinson Disease - drug therapy Parkinson Disease - physiopathology Pharmacology. Drug treatments Phenanthridines - adverse effects Phenanthridines - therapeutic use Placebos Therapeutic efficiency Human Chemotherapy Nervous system diseases Single dose D1 Dopamine receptor Dopamine agonist Parkinson disease Tolerance Degenerative disease
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	We carried out a double-blind rising dose study of a D-1 dopamine agonist, CY 208-243, in 6 parkinsonian patients. Deficits monitored by Columbia scores were significantly improved at single doses ranging from 5 to 40 mg, though efficacy was low. Used alone, CY 208-243 was not a satisfactory therapeutic agent, and toxicity data precluded further increases in dosage.
ISSN:	0028-3878 1526-632X
DOI:	10.1212/wnl.39.6.856